Novocure Ltd (NVCR) Stock AnalysisNVCRNovocure Ltd

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Novocure Ltd (NVCR) is a good buy right now due to its recent revenue growth of 16% year-over-year, reaching $183.6 million in Q2 2026, and a positive adjusted EBITDA of $10.8 million. The current price of $14.68 is significantly below the analyst price target of $52, indicating a strong upside potential. However, the forward P/E ratio is extremely high at 909.09, which poses a risk if growth does not materialize as expected.

6 analysts cover NVCR: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 23.58.